Watch this Wall Street Journal interview on why Dr. Wischik sees tau as a more worthwhile anti-Alzheimer's target than plaque. Learn more about TauRx' Alzheimer's trial drug called Rember.
WSJ's Shirley Wang spoke with Dr. Wischik about his work on this new drug to treat the devastating disease.
Comment or Share:
Post a Comment
Your comments (up to 200 words):